Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: A phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants

Journal of Clinical Psychiatry

Volumn 76, Issue 9, 2015, Pages 1224-1231

  Thase, Michael E ^a,c   Youakim, James M ^b   Skuban, Aleksandar ^b   Hobart, Mary ^b   Augustine, Carole ^b   Zhang, Peter ^b   McQuade, Robert D ^b   Carson, William H ^b   Nyilas, Margaretta ^a   Sanchez, Raymond ^b   Eriksson, Hans ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^c H LUNDBECK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BREXPIPRAZOLE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; PAROXETINE; PLACEBO; SERTRALINE; VENLAFAXINE; NEUROLEPTIC AGENT; QUINOLONE DERIVATIVE; THIOPHENE DERIVATIVE;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ADJUVANT THERAPY; ADULT; AGED; AKATHISIA; AMENORRHEA; ANORGASMIA; ANXIETY; ARTICLE; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EXTRAPYRAMIDAL SYMPTOM; FAINTNESS; FATIGUE; FEMALE; FRACTURE; GYNECOMASTIA; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERPROLACTINEMIA; INSOMNIA; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; METABOLIC SYNDROME X; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; PARKINSONISM; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SEXUAL DYSFUNCTION; SHEEHAN DISABILITY SCALE; SIDE EFFECT; SUICIDE; SUICIDE ATTEMPT; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; ADOLESCENT; ADVERSE EFFECTS; CLINICAL TRIAL; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DRUG COMBINATION; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; QUINOLONES; THIOPHENES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84942502416     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.14m09688     Document Type: Article

References (48)

1. Connolly KR, Thase ME. If at first you don't succeed: A review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs. 2011;71(1):43-64.
2. Han C, Yeh TL, Kato M, et al. Management of chronic depressive patients with residual symptoms. CNS Drugs. 2013;27(suppl 1): S53-S57.
3. Patkar AA, Pae CU. Atypical antipsychotic augmentation strategies in the context of guideline-based care for the treatment of major depressive disorder. CNS Drugs. 2013;27(suppl 1):S29-S37.
4. Croxtall JD, Scott LJ. Olanzapine/fluoxetine: A review of its use in patients with treatmentresistant major depressive disorder. CNS Drugs. 2010;24(3):245-262.
5. Pae CU, Sohi MS, Seo HJ, et al. Quetiapine XR: current status for the treatment of major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(7):1165-1173.
6. Sanford M. Quetiapine extended release: Adjunctive treatment in major depressive disorder. CNS Drugs. 2011;25(9):803-813.
7. Pae CU, Forbes A, Patkar AA. Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data. CNS Drugs. 2011;25(2):109-127.
8. Wright BM, Eiland EH 3rd, Lorenz R. Augmentation with atypical antipsychotics for depression: A review of evidence-based support from the medical literature. Pharmacotherapy. 2013;33(3):344-359.
9. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: A meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009;166(9):980-991.
10. Citrome L. Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: An analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Postgrad Med. 2010;122(4):39-48.
11. Spielmans GI, Berman MI, Linardatos E, et al. Adjunctive atypical antipsychotic treatment for major depressive disorder: A meta-analysis of depression, quality of life, and safety outcomes. PLoS Med. 2013;10(3):e1001403.
12. Millen BA, Campbell GM, Beasley CM. Weight changes over time in adults treated with the oral or depot formulations of olanzapine: A pooled analysis of 86 clinical trials. J Psychopharmacol. 2011;25(5):639-645.
13. Blier P. Neurotransmitter targeting in the treatment of depression. J Clin Psychiatry. 2013;74(suppl 2):19-24.
14. Moret C, Briley M. The importance of norepinephrine in depression. Neuropsychiatr Dis Treat. 2011;7(suppl 1):9-13.
15. Maeda K, Sugino H, Akazawa H, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonindopamine activity modulator. J Pharmacol Exp Ther. 2014;350(3):589-604.
16. Hirose T, Maeda K, Stensbol TB, et al. Synergistic effects of brexpiprazole with SSRI/SNRI/diazepam on forced swim test and marble burying behaviour in mice. Biol Psychiatry. 2014;75(suppl 1):132S.
17. Casey DE. Side effect profiles of new antipsychotic agents. J Clin Psychiatry. 1996;57(suppl 11):40-45, discussion 46-52.
18. Maeda K, Lerdrup L, Sugino H, et al. Brexpiprazole II: Antipsychotic-like and procognitive effects of a novel serotonindopamine activity modulator. J Pharmacol Exp Ther. 2014;350(3):605-614.
19. Thase ME, Fava M, Hobart M, et al. Efficacy of adjunctive OPC-34712 across multiple outcome measures in major depressive disorder: A phase II, randomized, placebo-controlled study. Neuropsychopharmacology. 2011;36:S302-S304.
20. Thase ME, Youakim JM, Skuban A, et al. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: A phase 3, randomized, double-blind study. J Clin Psychiatry. 2015;76(9):1232-1240.
21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
22. Chandler GM, Iosifescu DV, Pollack MH, et al. RESEARCH: Validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ). CNS Neurosci Ther. 2010;16(5):322-325.
23. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1): 56-62.
24. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6(4):278-296.
25. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare Publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1976:218-222.
26. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382-389.
27. Williams JBW, Kobak KA. Development and reliability of a structured interview guide for the Montgomery Asberg Depression Rating Scale (SIGMA). Br J Psychiatry. 2008;192(1):52-58.
28. Sheehan DV. The Anxiety Disease. New York, NY: Charles Scribner & Sons; 1983.
29. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol. 1996;11(suppl 3):89-95.
30. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-55.
31. Hamilton M. The diagnosis and rating of anxiety. In: Lader MH, ed. Studies of Anxiety. Kent: Br J Psychiatry Spec Publ; 1969:76-79.
32. Shear MK, Vander Bilt J, Rucci P, et al. Reliability and validity of a structured interview guide for the Hamilton Anxiety Rating Scale (SIGH-A). Depress Anxiety. 2001;13(4):166-178.
33. Williams JB. A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry. 1988;45(8):742-747.
34. Rush AJ, Gullion CM, Basco MR, et al. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med. 1996;26(3):477-486.
35. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand suppl. 1970;45(S212):11-19.
36. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154(5):672-676.
37. Chappell P, Feltner DE, Makumi C, et al. Initial validity and reliability data on the Columbia- Suicide Severity Rating Scale. Am J Psychiatry. 2012;169(6):662-663, author reply 663.
38. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266-1277.
39. Labbate LA, Lare SB. Sexual dysfunction in male psychiatric outpatients: validity of the Massachusetts General Hospital Sexual Functioning Questionnaire. Psychother Psychosom. 2001;70(4):221-225.
40. Duru G, Fantino B. The clinical relevance of changes in the Montgomery-Asberg Depression Rating Scale using the minimum clinically important difference approach. Curr Med Res Opin. 2008;24(5):1329-1335.
41. Montgomery SA, Moller HJ. Is the significant superiority of escitalopram compared with other antidepressants clinically relevant? Int Clin Psychopharmacol. 2009;24(3):111-118.
42. Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A multicenter, randomized, doubleblind, placebo-controlled study. J Clin Psychiatry. 2007;68(6):843-853.
43. Berman RM, Fava M, Thase ME, et al. Aripiprazole augmentation in major depressive disorder: A double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr. 2009;14(4):197-206.
44. Marcus RN, McQuade RD, Carson WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008;28(2):156-165.
45. Bauer M, Pretorius HW, Constant EL, et al. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry. 2009;70(4):540-549.
46. El-Khalili N, Joyce M, Atkinson S, et al. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: A multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2010;13(7):917-932.
47. Thase ME, Trivedi MH, Nelson JC, et al. Examining the efficacy of adjunctive aripiprazole in major depressive disorder: A pooled analysis of 2 studies. Prim Care Companion J Clin Psychiatry. 2008;10(6):440-447.
48. Lakoff A. The mousetrap: managing the placebo effect in antidepressant trials. Mol Interv. 2002;2(2):72-76.